Disclaimer: This is a simplified summary of a public company filing. See full disclaimer here.

Merus N.V.

CIK: 16513111 Annual ReportsLatest: 2025-04-07

10-K / April 7, 2025

Company Summary: Merus N.V.

Overview:

  • Merus N.V. is a biotechnology company based in the Netherlands.
  • The company focuses on developing innovative cancer immunotherapies, particularly antibody-based treatments.

Operational Details:

  • Location: Utrecht, The Netherlands (Uppsalalaan 17, 3584 CT Utrecht)
  • Primary Exchange & Symbol: Nasdaq Global Market, trading under the symbol MRUS
  • Shares Outstanding: 69,090,469 as of February 21, 2025
  • Market Capitalization (as of June 30, 2024): Approximately $3,996.5 million

Corporate Structure:

  • The company is incorporated and organized under Dutch law.
  • It is a large accelerated filer, indicating a substantial public company status.

Employees, Revenue, Income:

  • The document does not specify the number of employees.
  • Financial details such as revenue and income are not provided in this excerpt.

Business Focus:

  • Merus develops human monoclonal antibody therapies using its proprietary Biclonics® platform.
  • The company's therapies are aimed at treating various cancers by engaging the immune system to target and destroy tumor cells.
  • It operates through collaborations, licensing agreements, and its own R&D initiatives.

Regulatory & Reporting:

  • The company complies with SEC reporting requirements, having filed its annual report on Form 10-K/A.
  • It has an insider trading compliance policy in place but no specific financial results or customer count are disclosed.

Key Agreements and Policies:

  • It has various material contracts related to collaboration, licensing, and financing.
  • The company maintains a list of subsidiaries and has engaged major accounting firms such as KPMG for audits.

Additional Information:

  • The company emphasizes internal controls and adherence to Sarbanes-Oxley regulations.
  • The document mentions no financial statements are included in this amendment; details on revenue, net income, or customer numbers are not included.

Note: The provided document largely contains regulatory, corporate, and legal disclosures and does not specify detailed operational metrics such as number of customers, employee count, revenue, or net income.